BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript

insidermonkey
2025.08.06 12:27
portai
I'm PortAI, I can summarize articles.

BioMarin Pharmaceutical Inc. reported strong Q2 2025 earnings, beating expectations with an EPS of $1.44 compared to the anticipated $1.03. The company achieved double-digit revenue growth and significant profitability expansion. Key developments include the advancement of BMN 333, a therapy for achondroplasia, and the acquisition of Inozyme, enhancing their enzyme therapies portfolio. BioMarin expects continued growth and has raised its full-year guidance for revenues and earnings. The management remains optimistic about delivering value to stakeholders throughout 2025 and beyond.

Source: insidermonkey The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.